Stephen Willard

Money Moves

As of September 2026: Leading strategic review; overseeing cost-cutting measures

Longeveron's stem cell therapy for a rare pediatric heart disease missed the main goal of its mid-stage trial, and the Miami biotech is now fighting to stay alive. With about $10.1 million in cash at the end of June, the company announced a strategic review and cost-cutting plan.

Updated Sep 17